Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson : Pivotal Study of J&J's Covid-19 Vaccine to Resume, Company Says

10/23/2020 | 04:59pm EST

By Peter Loftus

Johnson & Johnson said Friday it is preparing to resume a large clinical trial of its experimental Covid-19 vaccine, saying it has found no evidence the vaccine caused a serious medical event in a study volunteer.

J&J had paused the trial earlier this month, citing an unexplained illness in a person enrolled in the trial. The trial began in September and is aiming to enroll up to 60,000 people in the U.S. and several other countries, to test whether a single dose safely protects people from Covid-19.

J&J said Friday an independent data safety and monitoring board has recommended resuming recruitment of study subjects for the trial. The New Brunswick, N.J., company consulted with U.S. regulators and is taking steps to resume the trial. It is also in discussion with regulators in other countries to resume testing there.

J&J didn't provide further details about the nature of the medical event in the study subject. The company said many possible factors could have caused it, and no clear cause has been identified.

Write to Peter Loftus at peter.loftus@wsj.com

(END) Dow Jones Newswires

10-23-20 1658ET

All news about JOHNSON & JOHNSON
11/23JOHNSON & JOHNSON : Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supple..
PU
11/23JOHNSON & JOHNSON : Initiates Second Global Phase 3 Clinical Trial of its Jansse..
PU
11/23JOHNSON & JOHNSON : New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) D..
PU
11/23JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
PU
11/23JOHNSON & JOHNSON : Late-Breaking 12-Month Data of Investigational RPGR Gene The..
PU
11/23JOHNSON & JOHNSON : Ex-dividend day for
FA
11/20COVID-19 VACCINES : What's Coming and When? -- 2nd -2-
DJ
11/20COVID-19 VACCINES : What's Coming and When? -- 2nd Update
DJ
11/18JOHNSON & JOHNSON : to Address Racial and Social Injustice through Platform that..
AQ
11/17J&J expects data for U.S. authorization of COVID-19 vaccine by Feb, says head..
RE
More news
Financials (USD)
Sales 2020 81 771 M - -
Net income 2020 15 967 M - -
Net Debt 2020 6 543 M - -
P/E ratio 2020 23,7x
Yield 2020 2,76%
Capitalization 379 B 379 B -
EV / Sales 2020 4,71x
EV / Sales 2021 4,26x
Nbr of Employees 132 200
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 164,73 $
Last Close Price 143,87 $
Spread / Highest target 25,1%
Spread / Average Target 14,5%
Spread / Lowest Target -3,39%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-3.77%283 004
MERCK & CO., INC.-11.73%203 111
PFIZER INC.-6.59%202 993
NOVARTIS AG-13.38%198 168
ABBVIE INC.15.41%180 396